News und Analysen
Lysogene to Provide Updates and Topline Results from Phase 2/3 AAVance Gene Therapy Clinical Study and Host Webcast on Wednesday, November 23, 2022
Regulatory News:
Lysogene (FR0013233475 – LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, today announced that it will host a live webcast on
LivaNova Receives 510(k) Clearance for ECMO from FDA for LifeSPARC, the Next-generation Advanced Circulatory Support System
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced it received 510(k) clearance for extracorporeal membrane oxygenation (ECMO) from the U.S
Vistagen Announces Publication in Cells Demonstrating AV-101’s Potential for Treating Levodopa-Induced Dyskinesia in Patients with Parkinson's Disease
Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system
Novocure Announces 25 Abstracts on Tumor Treating Fields Therapy at Society for Neuro-Oncology 2022 Annual Meeting
Novocure (NASDAQ: NVCR) today announced 25 abstracts on Tumor Treating Fields (TTFields) therapy will be featured at the Society for Neuro-Oncology (SNO) 2022 Annual Meeting from Nov. 16 to Nov. 20
Agilent Announces Cash Dividend of 22.5 Cents Per Share
Agilent Technologies Inc. (NYSE: A) today announced the company has increased its quarterly dividend to 22.5 cents per share of common stock, reflecting a 7% increase over the previous quarter. The
GeNeuro Announces Recruitment of First Patients in All Five Swiss Centers in the First Personalized Medicine Clinical Trial Against Long-COVID Assessing Temelimab
GeNeuro (Paris:GNRO)(Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases such
GeNeuro meldet erste Patientenrekrutierungen in allen fünf schweizerischen Zentren für die erste klinische Studie mit Temelimab zur personalisierten Medizin gegen Long COVID
GeNeuro (Euronext Paris: CH0308403085 - GNRO), ein biopharmazeutisches Unternehmen, das sich darauf konzentriert, die kausalen Faktoren zu stoppen, die das Fortschreiten von neurodegenerativen und
GeNeuro Announces Recruitment of First Patients in All Five Swiss Centers in the First Personalized Medicine Clinical Trial Against Long-COVID Assessing Temelimab
GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases such as multiple
Agilent to Present at the Evercore ISI HealthCONx Conference
Agilent Technologies Inc. (NYSE: A) today announced that Mike McMullen, president and chief executive officer, and Bob McMahon, chief financial officer, will present at the 5th Annual Evercore ISI
EQS-News: Abivax releases the results of its November 9, 2022 ad hoc ordinary and extraordinary general meeting
Simulations Plus and the University of Bath Awarded New FDA Grant
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that, through a joint proposal with
Agilent Announces AssayMAP Bravo Protein Sample Prep Workbench 4.0
Agilent Technologies Inc. (NYSE: A) today announced the release of the AssayMAP Bravo Protein Sample Prep Workbench 4.0 software. This release adds 21 CFR Part 11 compliance-enabling features that
Transgene and BioInvent Joint Paper on BT-001 Wins JITC “Best Oncolytic and Local Immunotherapy Paper” Award for 2022
Regulatory News:
Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, and BioInvent International AB
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with David Denton, Chief Financial Officer, Executive Vice President, at the Wolfe
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with David Denton, Chief Financial Officer, Executive Vice President, at the Wolfe
Novocure Secures CE Mark for New Array
Novocure (NASDAQ: NVCR) today announced receipt of CE Mark for its new polymer-based transducer array, called the flex array, designed for more efficient Tumor Treating Fields delivery and greater
Vistagen Reports Second Quarter Financial Results and Provides Corporate Update
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system
Savara Reports Third Quarter 2022 Financial Results and Provides Business Update
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the third quarter ending September 30, 2022 and provided
Xencor to Present at Upcoming Investor Conferences
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that
Xencor Presents Early Clinical Data from Combination Study of Vudalimab and New Data from Multiple Preclinical-stage XmAb® Programs at the SITC Annual Meeting
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the
Gustavo Mendes Lima Santos Joins the Simulations Plus Regulatory Fellowship Program
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that Gustavo Mendes Lima Santos has
Waters Highlights ESG Progress and New Commitments in its 2022 Report
Waters Corporation (NYSE:WAT) today released its 2022 Environmental, Social, and Governance (ESG) Report highlighting the company’s efforts for 2021 and the first half of 2022 to reduce its
CenterWell Senior Primary Care Brings Personalized Primary Care to Louisville, Opening 3 Centers by mid-2023
CenterWell Senior Primary Care will open three new senior-focused primary care centers in Louisville through mid-2023, marking the company’s debut in Kentucky and giving local seniors access to
Savara to Participate in Three Upcoming Investor Conferences
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate at the following investor
NanoString and Abcam Expand Collaboration to Advance Spatial Multiomics Research
NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, and Abcam (AIM: ABC; NASDAQ: ABCM), a global life science company